ReviewCancer science2009
The functioning antigens: beyond just as the immunological targets.
Review in Cancer science, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 40 citations in OpenAlex.
- Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients.Cancer science · 2013Trial
- Modulation of T cell function and survival by the tumor microenvironment.Frontiers in cell and developmental biology · 2023Review
- Phyto-Immunotherapy, a Complementary Therapeutic Option to Decrease Metastasis and Attack Breast Cancer Stem Cells.Frontiers in oncology · 2020Review
- Immune responses to human cancer stem-like cells/cancer-initiating cells.Cancer science · 2016Review
- T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2015Article
- MHC-restricted phosphopeptides from insulin receptor substrate-2 and CDC25b offer broad-based immunotherapeutic agents for cancer.Cancer research · 2014Article
- Heat shock protein DNAJB8 is a novel target for immunotherapy of colon cancer-initiating cells.Cancer science · 2014Article
- Photodynamic therapy of murine mastocytoma induces specific immune responses against the cancer/testis antigen P1A.Cancer research · 2013Article
- Identification of new HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from neuritin.Journal of neuro-oncology · 2013Article
- Circulating autoantibodies to LGALS3BP: a novel biomarker for cancer.Disease markers · 2013Article
- Chimeric infectious bursal disease virus-like particles as potent vaccines for eradication of established HPV-16 E7-dependent tumors.PloS one · 2012Article
- Cytotoxic T lymphocytes: Sniping cancer stem cells.Oncoimmunology · 2012Article
- Sipuleucel-T: immunotherapy for advanced prostate cancer.Open access journal of urology · 2011Review
- Strategies to target molecules that control the acquisition of a mesenchymal-like phenotype by carcinoma cells.Experimental biology and medicine (Maywood, N.J.) · 2011Review
- Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells.The American journal of pathology · 2011Article
- Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory T(H)2 cells via an IL-12- and OX40L-dependent pathway.Cancer cell · 2011Article
- Photodynamic therapy of tumors can lead to development of systemic antigen-specific immune response.PloS one · 2010Article
- Vaccines against human carcinomas: strategies to improve antitumor immune responses.Journal of biomedicine & biotechnology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antigenic peptides derived from tumor-associated antigens (TAAs) facilitate peptide cancer vaccine therapies. With the recent progress in cancer immunity research, huge amounts of antigenic peptides have already been reported. Clinical trials using such peptides are underway now all over the world. Some reports have shown the efficacy of peptide vaccine therapies. However, others ended with unfavorable results, suggesting fundamental underlying problems. One major mechanism that negates the peptide vaccine therapy is tumor escape from immunological systems caused by loss of antigens. TAAs that are used in cancer vaccine therapies may be divided into two major groups: functioning antigens and nonfunctioning antigens. A 'functioning antigen' could be defined as a TAA that is essential for tumor growth, is expressed in several kinds of malignancies and shows homogenous expression in cancerous tissues. It is not difficult to imagine that antigen loss will occur easily with non-functioning antigens as a target of cancer vaccine therapy. Thus, it is essential to use functioning antigens for successful cancer vaccine therapy. In this review, we discuss the functioning antigens and their categorization in detail.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.